Cyclocurcumin is a potent p38α inhibitor. Cyclocurcumin shows antirheumatic, antivasoconstrictive and antioxidant activities .
In Vitro
Cyclocurcumin (10-40 μM; 18 h) leads to significant inhibition in the release of TNF-α in a dose-dependent manner in LPS-stimulated human macrophages. Cyclocurcumin (5-25 μM) inhibits phenylephrine (HY-B0769)-induced vasocontraction in a concentration-dependent manner (IC 50 =14.9±1.0 μM) in freshly isolated rat aortic rings. Cyclocurcumin (5-25 μM; 30 min) inhibits influx of intracellular calcium in a dose-dependent manner. Cyclocurcumin inhibits L-type calcium channel-mediated vasoconstriction in a concentration-dependent manner. The anticontractile effect of Cyclocurcumin is reversible. Cyclocurcumin has strong activity as a scavenger of ˙OH and ˙OOH free radicals preferentially by its 4′-OH phenolic radical via a hydrogen-atom transfer mechanism in water and a physiological environment. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
